Rigel Pharmaceuticals (RIGL) Balance Sheet: Assets & Liabilities

Rigel Pharmaceuticals (RIGL) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Rigel Pharmaceuticals reported total assets of $513.59M and total liabilities of $122.11M. Shareholders' equity was $391.48M, up 11806.3% from $3.29M a year earlier. Total debt stood at $53.30M against $154.96M in cash and short-term investments, a net cash position of $101.65M. That puts debt-to-equity at 0.14, compared with 18.15 a year earlier.

Rigel Pharmaceuticals Balance Sheet Analysis

Values in billions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Rigel Pharmaceuticals, Inc. (RIGL) - Annual data in billions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Current Assets
Cash and Cash Equivalents	0.04	0.06	0.03	0.02	0.02	0.03	0.02	0.08	0.04
Short-Term Investments	0.11	0.02	0.02	0.03	0.11	0.03	0.08	0.05	0.08
Cash & Short-Term Investments	0.15	0.08	0.06	0.06	0.12	0.06	0.10	0.13	0.12
Accounts Receivable	0.05	0.04	0.03	0.04	0.02	0.02	0.01	0.00	0.00
Inventory	0.01	0.01	0.01	0.02	0.01	0.01	0.00	0.00	0.00
Other Current Assets	0.02	0.00	0.01	0.01	0.01	0.01	0.01	0.01	0.00
Total Current Assets	0.24	0.14	0.10	0.12	0.15	0.09	0.12	0.14	0.12
Non-Current Assets
Property, Plant & Equipment (Net)	0.00	0.00	0.00	0.00	0.01	0.02	0.03	0.00	0.00
Intangible Assets	0.02	0.03	0.01	0.01	0.00	0.00	0.00	0.00	0.00
Other Non-Current Assets	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Non-Current Assets	0.27	0.03	0.02	0.02	0.01	0.02	0.03	0.00	0.00
Total Assets	0.51	0.16	0.12	0.13	0.17	0.11	0.15	0.14	0.12
Current Liabilities
Accounts Payable	0.01	0.00	0.01	0.02	0.00	0.00	0.00	0.01	0.00
Short-Term Debt	0.03	0.01	0.01	0.00	0.01	0.01	0.01	0.00	0.00
Current Portion of Long-Term Debt	0.03	0.01	0.01	0.00	0.01	-	-	-	-
Accrued Liabilities	0.02	0.01	0.01	0.02	0.02	0.02	-	-	-
Deferred Revenue	0.00	0.03	0.02	0.00	0.01	0.00	0.03	0.00	0.00
Other Current Liabilities	0.06	0.02	0.02	0.02	0.01	0.00	0.02	0.02	0.02
Total Current Liabilities	0.10	0.06	0.05	0.07	0.06	0.04	0.06	0.03	0.02
Non-Current Liabilities
Long-Term Debt	0.02	0.05	0.05	0.04	0.02	0.02	0.03	0.00	0.00
Other Non-Current Liabilities	0.00	0.04	0.04	0.04	0.05	0.01	0.01	0.00	0.00
Total Non-Current Liabilities	0.02	0.10	0.09	0.08	0.07	0.04	0.04	0.00	0.00
Total Liabilities	0.12	0.16	0.15	0.15	0.14	0.08	0.09	0.03	0.02
Stockholders' Equity
Common Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Retained Earnings	-1.02	-1.39	-1.41	-1.38	-1.32	-1.31	-1.28	-1.21	-1.14
Accumulated Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Additional Paid-in Capital	1.41	1.39	1.38	1.37	1.35	1.34	1.33	1.32	1.24
Shares Outstanding	0.02	0.02	0.02	0.02	0.02	-	-	-	-
Total Stockholders' Equity	0.39	0.00	-0.03	-0.01	0.03	0.03	0.05	0.11	0.10
Total Liabilities & Equity	0.51	0.16	0.12	0.13	0.17	0.11	0.15	0.14	0.12

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Rigel Pharmaceuticals Balance Sheet

How much debt does Rigel Pharmaceuticals have?

Rigel Pharmaceuticals had total debt of $53.30M as of Dec 31, 2025, against $154.96M in cash and short-term investments. Its debt-to-equity ratio was 0.14. Total debt was $59.68M a year earlier.

What are Rigel Pharmaceuticals's total assets?

Rigel Pharmaceuticals reported total assets of $513.59M as of Dec 31, 2025, up 213.2% from $163.98M a year earlier. Total liabilities were $122.11M.

What is Rigel Pharmaceuticals's shareholders' equity?

Rigel Pharmaceuticals's shareholders' equity was $391.48M as of Dec 31, 2025, or about $21.38 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition